Stock Market & Financial Investment News

News Breaks September 4, 2012 08:14 EDT IPXL, SNY Impax reaches settlement with Sanofi relating to RENVELA and RENAGEL Impax Laboratories (IPXL) announced that it has reached agreement with Genzyme, a Sanofi company (SNY), to settle pending U.S. litigation with regard to the production and sale of generic formulations of RENVELA and RENAGEL. Under the terms of the settlement, Genzyme has agreed to grant Impax a license to sell a generic version of RENVELA tablets on March 16, 2014 or earlier under certain circumstances. Genzyme has also agreed to grant Impax a license to sell a generic version of RENVELA for oral suspension and of RENAGEL on September 16, 2014 or earlier under certain circumstances. The Company believes that it is the first to file an ANDA with a paragraph IV certification with respect to the sevelamer carbonate 800 mg tablet product, and expects to be entitled to 180-days of market exclusivity prior to the launch of additional ANDA products. Upon the agreed-upon launch dates, Global Pharmaceuticals, Impax’s generic division, intends to commercialize the products. RENAGEL and RENVELA are both indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis. News For IPXL;SNY From The Last 14 Days Check below for free stories on IPXL;SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 08:18 EDT SNY Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi Subscribe for More Information May 22, 2013 07:28 EDT IPXL UBS to host a conference Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information May 17, 2013 08:41 EDT IPXL Impax commenced shipment of authorized generic Zomig Impax (IPXL) announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig tablets, as part of an agreement with AstraZeneca (AZN). Zomig is indicated for the treatment of migraine headaches in adults. According to IMS Health data, U.S. sales of Zomig tablets and orally disintegrating tablets were approximately $196M in the 12 months ended April 2013. 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:49 EDT IPXL FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. May 10, 2013 11:48 EDT SNY Drugmakers to face pressure on U.S. prices, Reuters says Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.